

Study Group – Liver tumors

Prospective documentation of risk factors, treatment modalities and outcome in a data integration platform to optimize therapeutic concepts in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCC)

Speaker: Prof. Dr. med. Hans J. Schlitt, Regensburg / PD Dr. Ursula Ehmer, Munich


Concept & Achievements

Background and Concept

Primary liver cancer is tumor entity with rising incidence and – despite recent advances in treatment options – dismal prognosis. HCC, the most common primary liver cancer, occurs in the background of pre-existing liver disease in the majority of cases. **Diverse risk factors** including metabolic dysfunction-associated fatty liver disease, excessive alcohol consumption, and chronic viral hepatitis **contribute to the development of HCC**. Presence of these **risk factors might influence treatment response** – a hypothesis not yet proven in large real-world cohort.

Treatment in HCC is stage dependent and **based on multimodal treatment concepts** – including surgery, transarterial or percutaneous interventional therapies, and systemic treatment options.

With establishment of the **liver cancer Data Integration System (DIS)**, a detailed **longitudinal documentation and analysis in a large liver cancer patient cohort** can be generated to reflect tumor and patient heterogeneity and to understand the impact of therapy on disease progression.



Achieved Milestones Data:

- » Implementation of a liver cancer Data Integration System (DIS)
- » Begin of Data collection

In addition to data collection, planning and **start-up of two clinical trials** and **completion of a retrospective analysis** of adverse events in systemic treatment in HCC was achieved within the BZKF study group..

Achieved Milestones Clinical Trials:

- » **HOMIE-166:** radioembolization of HCCs with Holmium (¹⁶⁶Ho) all 6 BZKF centers (lead: Jens Ricke, LMU): planning and financing
- » **MONTBLANC:** medical oncology trial in first line systemic HCC treatment (lead: Enrico de Toni, LMU): initiation and recruitment in progress
- » **Retrospective analysis:** bleeding and thromboembolic events after systemic treatment of HCC (lead: Florian Reiter, WÜ): completed

Achievements and milestones

To establish the prospective liver cancer cohort, **a web-based DIS has been created to collect patient-reported outcomes and standardized clinical parameters** including radiology, histology, liver function parameters and treatment outcome.

Future Milestones

- » Prospective data collection in liver cancer patients
- » Expansion of the data integration system to include patients with iCCC
- » Integration of a detailed structured radiology report for HCC into the HCC DIS (collaboration with BORN project)
- » Initiation and recruitment of BZKF clinical trials (HOMIE-166, MONTBLANC)
- » Biobanking and analysis of tumor and blood samples (cf-DNA, PBMC) within BZKF clinical trials
- » Data read-out and analysis of risk factors, diagnostic features, and therapeutic outcome

Authors: Ursula Ehmer⁴, Thomas Kröncke¹, Tobias Weber¹, Peter Dietrich², Georg Weber², Najib Ben Khaled³, Enrico De Toni³, Jens Ricke³, Daniel Hartmann⁴, Matthias Evert⁵, Florian Reiter⁶, Andreas Geier⁶, Lisa Fricke⁴, Hans J. Schlitt⁵

¹Universitätsklinikum Augsburg, ²Universitätsklinikum Erlangen, ³LMU Klinikum München, ⁴Klinikum rechts der Isar der TU München

⁵Universitätsklinikum Regensburg, ⁶Universitätsklinikum Würzburg